KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Discontinued OperationsCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TherapeuticsMD (TXMD) Long-Term Debt Repayments (2021 - 2022)

TherapeuticsMD's Long-Term Debt Repayments history spans 5 years, with the latest figure at $94.4 million for Q4 2022.

  • For Q4 2022, Long-Term Debt Repayments changed N/A year-over-year to $94.4 million; the TTM value through Dec 2022 reached $334.4 million, up 568.86%, while the annual FY2022 figure was $219.4 million, 338.86% up from the prior year.
  • Long-Term Debt Repayments reached $94.4 million in Q4 2022 per TXMD's latest filing, down from $120.0 million in the prior quarter.
  • In the past five years, Long-Term Debt Repayments ranged from a high of $120.0 million in Q1 2022 to a low of $50.0 million in Q1 2021.